適體市場規模、佔有率、成長分析、按類型、應用、技術、最終用戶、地區 - 產業預測，2025 年至 2032 年

適體市場規模預計在 2023 年達到 29.1 億美元，並將從 2024 年的 36.3 億美元成長到 2032 年的 210.6 億美元，預測期內（2025-2032 年）的複合年成長率為 24.6%。

由於慢性病盛行率的上升和標靶治療的日益普及，全球適體市場預計將顯著成長。對早期診斷解決方案的需求，加上對創新診斷技術不斷增加的投資，可能會進一步推動該市場向前發展。此外，試管內選擇（SELEX）技術的進步有望增加適體開發的機會。醫學研究和開發的激增，加上人們對基因治療的興趣日益濃厚以及對適體益處的認知不斷提高，為市場強勁擴張奠定了基礎。然而，半衰期短、替代品可用性、可接受性有限以及法律規範嚴格等挑戰可能會阻礙其發展。特別是美國和加拿大等新興前沿地區已成為適體供應商的有前景的市場。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 二次資料和一次資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態與展望

• 市場概覽
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024年）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 案例研究
• 監管格局

適體市場規模（按類型）

• 市場概覽
• DNA適體
• RNA適體
• XNA適體
• 胜肽適體
• 適體-藥物偶聯物（ApDC）

適體市場規模：按應用

• 市場概覽
• 診斷
  • 生物標記檢測
  • 病原體檢測
  • 顯影劑
  • 伴同性診斷
• 治療
  • 腫瘤學
  • 心血管疾病
  • 感染疾病
  • 眼科
  • 發炎與自體免疫疾病
• 研究與開發
  • 分子探針
  • 目標檢驗
  • 蛋白質相互作用研究
• 生物感測器
  • 環境監測
  • 食品安全
  • 生物防禦應用
• 藥物輸送系統
  • 定向投放
  • 控釋製劑

適體市場規模：依技術分類

• 市場概覽
• 賽萊克斯
  • 常規 SELEX
  • 細胞SELEX
  • 毛細管電泳SELEX
  • 微流體SELEX
  • 高通量SELEX
• SELEX 後最佳化技術
  • 化學改性
  • 截斷
  • 二聚化
  • 聚乙二醇

按最終用戶分類的適體市場規模

• 市場概覽
• 製藥和生物技術公司
• 學術研究所
• 臨床實驗室
• 合約研究組織（CRO）
• 診斷實驗室

適體市場規模

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024年）
• 主要企業簡介
  • 公司詳情
  • 產品系列分析
  • 公司分部佔有率分析
  • 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

• Aptamer Group（UK）
• Aptadel Therapeutics（USA）
• SomaLogic Operating Co., Inc.（USA）
• Base Pair Biotechnologies（USA）
• Vivonics, Inc.（USA）
• Aptagen, LLC（USA）
• Aptus Biotech（Spain）
• TriLink BioTechnologies（USA）
• AM Biotechnologies, LLC（USA）
• Maravai LifeSciences（USA）

結論和建議

Aptamers Market size was valued at USD 2.91 billion in 2023 and is poised to grow from USD 3.63 billion in 2024 to USD 21.06 billion by 2032, growing at a CAGR of 24.6% during the forecast period (2025-2032).

The global market for aptamers is poised for significant growth, driven by the rising prevalence of chronic diseases and the increasing adoption of targeted therapeutics. The demand for early diagnostic solutions, backed by heightened investments in innovative diagnostic technologies, will further propel this market forward. Additionally, advancements in SELEX technology are expected to enhance aptamer development opportunities. The surge in medical research and development, coupled with a growing focus on genetic therapies and heightened awareness of aptamer benefits, positions the market for robust expansion. However, challenges such as short half-life, availability of alternatives, limited acceptance, and stringent regulatory frameworks may hinder growth. Notably, developed regions like the United States and Canada are emerging as promising markets for aptamer providers.

Top-down and bottom-up approaches were used to estimate and validate the size of the Aptamers market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Aptamers Market Segments Analysis

Global Aptamers Market is segmented by Type, Application, Technology, End-User and region. Based on Type, the market is segmented into DNA Aptamers, RNA Aptamers, XNA Aptamers, Peptide Aptamers and Aptamer-drug conjugates (ApDCs). Based on Application, the market is segmented into Diagnostics, Therapeutics, Research & Development, Biosensors and Drug Delivery Systems. Based on Technology, the market is segmented into SELEX and Post-SELEX Optimization Techniques. Based on End-User, the market is segmented into Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Clinical Laboratories,Contract Research Organizations(CROs) and Diagnostic Laboratories. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Aptamers Market

The aptamers market is being propelled by the increasing investments in the advancement of drug delivery technologies, which have facilitated the emergence of targeted therapeutics. These therapeutics are gaining widespread acceptance globally due to their ability to minimize unexpected side effects, offering a safer alternative to traditional treatments. As a result, the utilization of aptamers in the development of these specialized drugs is contributing significantly to the growth of the market. With the rising demand for targeted therapies, the role of aptamers as key components in innovative drug development is becoming more prominent, driving further evolution in this sector.

Restraints in the Aptamers Market

The Aptamers market faces a significant constraint due to the notably brief half-life of aptamers, which typically spans just minutes to hours. This limited duration poses substantial challenges in identifying viable practical applications for these molecules. Efforts to manage the short half-life while preserving the unique characteristics of aptamers without degradation present a formidable obstacle. Consequently, these difficulties are anticipated to hinder the growth and demand for aptamers in the market in the coming years, as researchers and manufacturers struggle to optimize their stability and functionality for effective use in various applications.

Market Trends of the Aptamers Market

The global aptamer market is witnessing a significant trend towards the incorporation of chemical modifications to enhance aptamer stability and functionality. As researchers and aptamer providers increasingly focus on innovations such as PEGylation and locked nucleic acid (LNA) modifications, the market is expected to expand due to improvements in pharmacokinetics, target binding, and reduced degradation in biological systems. These advancements will not only broaden the application scope of aptamers in therapeutics and diagnostics but also cater to the growing demand for more efficient and durable biotherapeutics, positioning modified aptamers as a pivotal element in the biotechnology landscape.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Regulatory Landscape

Global Aptamers Market Size by Type & CAGR (2025-2032)

• Market Overview
• DNA Aptamers
• RNA Aptamers
• XNA Aptamers
• Peptide Aptamers
• Aptamer-drug conjugates (ApDCs)

Global Aptamers Market Size by Application & CAGR (2025-2032)

• Market Overview
• Diagnostics
  • Biomarker Detection
  • Pathogen Detection
  • Imaging Agents
  • Companion Diagnostics
• Therapeutics
  • Oncology
  • Cardiovascular Diseases
  • Infectious Diseases
  • Ophthalmology
  • Inflammatory & Autoimmune Diseases
• Research & Development
  • Molecular Probes
  • Target Validation
  • Protein Interaction Studies
• Biosensors
  • Environmental Monitoring
  • Food Safety
  • Biodefense Applications
• Drug Delivery Systems
  • Targeted Delivery
  • Controlled Release Formulations

Global Aptamers Market Size by Technology & CAGR (2025-2032)

• Market Overview
• SELEX
  • Conventional SELEX
  • Cell-SELEX
  • Capillary Electrophoresis SELEX
  • Microfluidic SELEX
  • High-throughput SELEX
• Post-SELEX Optimization Techniques
  • Chemical Modifications
  • Truncation
  • Dimerization
  • PEGylation

Global Aptamers Market Size by End-User & CAGR (2025-2032)

• Market Overview
• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• Clinical Laboratories
• Contract Research Organizations (CROs)
• Diagnostic Laboratories

Global Aptamers Market Size & CAGR (2025-2032)

• North America (Type, Application, Technology, End-User)
  • US
  • Canada
• Europe (Type, Application, Technology, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Application, Technology, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Application, Technology, End-User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Application, Technology, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Aptamer Group (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aptadel Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SomaLogic Operating Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Base Pair Biotechnologies (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vivonics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aptagen, LLC (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aptus Biotech (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• TriLink BioTechnologies (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AM Biotechnologies, LLC (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Maravai LifeSciences (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations